Literature DB >> 17568950

Merozoite surface protein 2 allelic variation influences the specific antibody response during acute malaria in individuals from a Brazilian endemic area.

Selma Sallenave-Sales1, Clarissa Perez Faria, Mariano Gustavo Zalis, Cláudio Tadeu Daniel-Ribeiro, Maria de Fátima Ferreira-da-Cruz.   

Abstract

The antibody response to Plasmodium falciparum parasites of naturally infected population is critical to elucidate the role of polymorphic alleles in malaria. Thus, we evaluated the impact of antigenic diversity of repetitive and family dimorphic domains of the merozoite surface protein 2 (MSP-2) on immune response of 96 individuals living in Peixoto de Azevedo (MT-Brazil), by ELISA using recombinant MSP-2 proteins. The majority of these individuals were carrying FC27-type infections. IgG antibody responses were predominantly directed to FC27 parasites and were correlated to the extension of polymorphism presented by each MSP-2 region. This finding demonstrated the impact of the genetic polymorphism on antibody response and therefore, its importance on malaria vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568950     DOI: 10.1590/s0074-02762007005000048

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  2 in total

1.  Genetic diversity in merozoite surface protein-1 and 2 among Plasmodium falciparum isolates from malarious districts of tribal dominant state of Jharkhand, India.

Authors:  M M Hussain; M Sohail; R Kumar; O H Branch; T Adak; M Raziuddin
Journal:  Ann Trop Med Parasitol       Date:  2011-12

2.  Genetic diversity and antibody responses against Plasmodium falciparum vaccine candidate genes from Chhattisgarh, Central India: Implication for vaccine development.

Authors:  Priyanka Patel; Praveen K Bharti; Devendra Bansal; Rajive K Raman; Pradyumna K Mohapatra; Rakesh Sehgal; Jagadish Mahanta; Ali A Sultan; Neeru Singh
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.